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ABSTRACT 
The objective of the present study was to prepare immediate release tablets (IRTs) of deflazacort by direct compression method. Two types of 
superdisintegrants i.e. sodium starch glycolate (SSG) and Ac-Di-sol were used in the formulation of tablets. Twelve preliminary batches were 
prepared by varying the concentration of superdisintegrants. It was found that formulation containing Ac-Di-Sol disintegrated in less time as 
compared to formulation containing sodium starch glycolate. Values of friability was found to be more in case of formulation containing Ac-Di-
Sol. Attempts were also made to prepare the tablets containing superdisintegrants in combination and these resulted in the formulation with 
improved values of disintegration time and friability. On the basis of preliminary studies optimization of IRT was done employing 32 full factorial 
design using design expert 7. The optimized batch of IRTs showed friability and disintegration time values of 0.598 and 64.17±3.50 respectively. 
It was also found that 96.26±1.82% of drug was released within 5 min. 
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INTRODUCTION 
Oral route is the preferred route of administration for 
administering therapeutic agents. Rate of absorption of drug 
is controlled by rate of dissolution. Rate of dissolution can be 
increased by various methods. In present study IRTs were 
formulated that disintegrate in less time delivering fine 
suspension of particles of drug with large surface area, 
resulting in increased rate of dissolution1. Deflazacort was 
chosen as the model drug. Solubility of deflazacort is low 
thus making its dissolution controlled by disintegration. 
Deflazacort is a corticosteroid which is an oxazoline 
derivative of prednisolone, characterized by a high binding 
affinity to tissue glucocorticoid receptors and exert anti-
inflammatory and immunosuppressive effects. Deflazacort 
significantly inhibits both the proliferation of mononuclear 
cells derived from human peripheral blood, and the release 
of inflammatory cytokines by these cells. Thus deflazacort is 
rapidly effective in symptoms and objective indices of 
disease activity in rheumatoid arthritis2. RA is a chronic 
disorder in which, the body's own immune system starts to 
attack body tissues, reasons of which are unknown. This 
disorder is accompanied with swelling, stiffness and pain. In 
this disorder the attack is not only directed at the joint but to 
many other parts of the body. In RA, the joint lining and 
cartilage gets more damaged which eventually results in 
erosion of two opposing bones. Based on the studies, it has 
been reported that deflazacort could be used in treatment of 
RA. It is as efficacious as prednisolone with less adverse 
effects as compared to other corticosteroids3.  
In the formulation of immediate release tablets basic 
approach is to use superdisintegrants. In the present study 
two types of superdisintegrants (sodium starch glycolate and 
Ac-Di-Sol) were used. Concentration of both 
superdisintegrants was optimized by employing 32 full 
factorial design. 
MATERIALS AND METHOD 
Materials 
Deflazacort and Avicel pH101 was obtained from Oscar 
Remedies Pvt. Ltd. Haryana, India. Sodium starch glycolate, 
talc and magnesium stearate was obtained from Nice 
Chemicals Pvt. Ltd. Kerala, India. Ac-Di-Sol was obtained 
from Optica Pharmaceuticals, Haryana, India. 
Raina et al                                                                                                                  Journal of Drug Delivery & Therapeutics. 2019; 9(2):250-254 
ISSN: 2250-1177                                                                                     [251]                                                                                     CODEN (USA): JDDTAO 
Methods 
Preparation of immediate release tablets 
Based on composition of deflazacort IRT tablets with 
deflazacort IRT tablet depicted in table 1 6mg deflazacort 
and excipients (except the lubricant; magnesium stearate 
and glidant ; talc) were physically mixed by geometric 
mixing. Powdered mixture was passed through 60 # sieve 
and blended properly using a mortar and pestle. The 
resultant blend was lubricated with the addition of lubricant 
and glidant and finally compressed into tablets (30 
mg) using 3 mm round flat punches. Machine settings were 
adjusted to get the desired hardness value, which gave an 
intact tablet. 
 
Table 1: Composition of preliminary trial batches of immediate release tablets 
Ingredients 
(mg) 
Formulation Code 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
Deflazacort 6 6 6 6 6 6 6 6 6 6 6 6 
SSG 0.6 1.201 1.802 2.403 - - - - 0.6 0.6 1.802 2.40 
Ac-Di-Sol - - - - 0.6 1.201 1.802 2.403 0.6 1.802 0.6 2.40 
Talc 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 
Mag. stearate 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 
Avicel pH101 22.5 21.99 21.39 20.79 22.5 21.89 21.29 20.697 21.9 20.69 20.69 18.29 
 
Evaluation 
The prepared immediate release tablets were evaluated for 
weight variation and thickness. Using micrometer thickness 
was determined for twenty tablets4. Weight variation of 
prepared tablets was determined as per USP5 by taking 
twenty tablets and comparing average weight with the 
individual weight of tablets. Hardness of ten tablets6 from 
each batch was determined using pfizer hardness tester and 
Friability of all batches of IRT was determined as per USP7 
using Roche friabilator. Sample of whole tablets 
corresponding to about 6.5 g was placed in the friabilator 
and were subjected to 100 revolutions. 
The prepared IRTs were subjected to assessment of in-vitro 
disintegration time using USP-27/NF-22 disintegration test 
apparatus8. Drug content of prepared IRTs were carried out 
by crushing ten tablets in a glass mortar and transferred 
quantitatively with methanol in a stoppered conical flask. 
The flask was placed in a sonicator for 30 min. The mixture 
was filtered and an aliquot, following suitable dilution, was 
analyzed at 242 nm using a UV spectrophotometer9.  
In vitro release study 
The dissolution studies of prepared IRTs were carried out 
using USP type II dissolution test apparatus10. The tablets 
were placed in dissolution vessel containing 900 ml of  
phosphate buffer pH 6.8 maintained at 37ºC ± 0.5 and stirred 
at 75 rpm. Samples (6 ml) were collected periodically at 
different time intervals (1, 2, 4, 6, 8, 10, 15, 20, 25, 30 min) 
and replaced with fresh dissolution medium. The absorbance 
was determined spectrophotometrically at 242 nm. 
Dissolution profiles were constructed as shown in Fig. 1 
Concentrations were calculated using calibration curves 
developed in respective media. 
Experimental design 
A two factor, three level (32) FFD was used in the 
optimization of IRTs of deflazacort. The study design 
involved the investigation of the effect of independent 
variables i.e. concentration of Sodium starch glycolate (X1) 
and concentration of Ac Di Sol (X2) on the dependent 
variables such as disintegration time, and friability. The 
levels of the factors study was selected on the basis of 
preliminary studies. Concentration of sodium starch 
glycolate (2, 4, 6%) and Ac-Di-Sol (6, 7, 8%) were selected as 
independent factors X1 and X2 respectively. Combination of 
these trials is represented in table 2. Nine formulations 
(Table 3) were prepared according to experimental design.
 
Table 2: Experimental plan of 32 full factorial design 
F. Code SSG Concentration (X1) Ac Di SolConcentration (X2) 
CT1 -1 -1 
CT2 0 -1 
CT3 +1 -1 
CT4 -1 0 
CT5 0 0 
CT6 +1 0 
CT7 -1 +1 
CT8 0 +1 
CT9 +1 +1 
Table 3: Formulation of experimental batches of Immediate release tablets 
Ingredients (mg) CT1 CT2 CT3 CT4 CT5 CT6 CT7 CT8 CT9 
Deflazacort 6 6 6 6 6 6 6 6 6 
SSG 0.6 1.2 1.8 0.6 1.2 1.8 0.6 1.2 1.8 
Ac-Di-Sol 1.8 1.8 1.8 2.1 2.1 2.1 2.4 2.4 2.4 
Talc 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 
Magnesium stearate 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 
Avicel PH101 20.7 20.1 19.5 20.4 19.8 19.2 20.1 19.5 18.9 
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Optimization of IRT 
The optimization process was used to obtain a model 
equation (Y = B0 + B1X1 + B2 X2 + B3 X1 X2 + B4 X1 2 + B5 
X2 2) that provides a means of evaluating changes in 
response due to changes in the independent variable levels. 
After application of full factorial design and with help of 
polynomial terms the optimized tablet (C1) was produced. 
Tablets were prepared as per composition given in table 4. 
This batch targeted to the friability 0.566 and 
disintegration time of 63.773 s. The observed response for 
friability and disintegration time were 0.598 and 
64.167±3.502 respectively. 
 
Table 4: Composition of optimum batch (C1) of immediate release tablet 
Batch Deflazacort SSG Ac-Di-Sol Talc Magnesium stearate Avicel pH101 
C1 6 1.8 1.974 0.6 0.3 19.36 
 
Stability studies 
To assess the stability of formulation, the optimum IRTs 
were packed in an amber colored air tight vial and stored 
at (40 ± 2 °C and 75 ± 5% RH) for a period of 6 months. 
The tablets were withdrawn after a particular period of time, 
analyzed for physical appearance, weight, hardness, 
friability, disintegration time, drug content, and % drug 
release. At this point, the data was statistically analyzed 
using ANOVA to test the significance of difference at the level 
of significance 0.05. 
RESULTS AND DISCUSSION 
Evaluation of preliminary FDT batches and experimental 
batches   
Preliminary batches of IRT of deflazacort were prepared by 
direct compression method employing sodium starch 
glycolate and Ac-Di-Sol as superdisintegrants. Directly 
compressible Avicel PH 101, was used as diluent. A total of 
twelve formulations were designed, in formulation F1-F4 
and F5-F8 varying concentration of sodium starch glycolate 
and Ac-Di-Sol were incorporated respectively. F9-F12 
formulations were prepared, containing both sodium starch 
glycolate and Ac-Di-Sol in different concentrations. Low 
Hausner’s ratio (≤ 1.32), compressibility index (≤ 24.68) and 
angle of repose (≤ 18.13) values indicated a fairly good flow 
ability of powder mixture as per Setty et al. 200811. All the 
formulations exhibited uniform weight, as per USP5 with low 
standard deviation values, indicating the uniformity of the 
tablets prepared by direct compression method. Average 
tablet thickness was found to be within limits (± 5%) 
(Banker et al. 198712 and Beringer et al. 200513). The % 
friability of all the formulations was found to be 0.372–0.898. 
Results of preliminary batch are shown in Table 5. 
On the basis of preliminary studies it was found that with 
increase in concentration of SSG and Ac-Di-Sol tablets 
disintegrated in less time and value of friability increased. 
Disintegration time of tablets containing SSG was more as 
compared to tablets containing Ac-Di-Sol, whereas friability 
value was more in case of tablets containing Ac-Di-Sol. Thus 
based on this study both SSG and Ac-Di-Sol were used 
together for further studies. Drug content of randomly 
selected ten tablets were determined and it was found that 
obtained values were within the limits as per USP. Obtained 
data for experimental batch was found to be between 97.34-
103.17%.
 
Table 5: Characterization of preliminary batch of compressed immediate release tablets 
F. 
Code 
Weight variation 
(mg) (Mean±SD)*** 
Thickness (mm)                                                                                                  
(Mean±SD)*** 
Hardness
(Kg/cm2) 
**** 
Drug
content 
Friability
(%)***** 
Disintegration 
time (sec)****** 
F1 30.25±2.50 3.3449±0.089 3.166±.057 99.83 0.372 621.000±3.605 
F2 29.6±2.258 3.5576±0.086 3.067±0.173 99.76 0.402 234.667±4.163 
F3 31.15±1.579 3.6953±0.112 2.867±0.100 99.74 0.442 227.333±3.177 
F4 31.4±2.627 3.8069±0.128 2.633±0.208 99.69 0.575 183.667±5.507 
F5 28.15±2.998 3.4608±0.074 2.935±.058 99.87 0.398 147.667±2.516 
F6 30.75±1.762 3.6313±0.097 2.8±0.153 99.82 0.447 114.000±4.582 
F7 30.25±2.417 3.48±0.103 2.667±0.142 101.2 0.533 70.000±3.605 
F8 29.6±2.208 3.520±.154 2.433±0.153 98.51 0.617 56.667±3.512 
F9 31.15±2.852 3.510±.099 2.867±0.208 102.21 0.425 129.667±4.509 
F10 30.4±2.577 3.59±0.087 2.767±0.058 97.71 0.614 60.000±3.605 
F11 28.15±2.998 3.46±0.117 2.905±0.100 98.13 0.579 114.000±4.582 
F12 32.75±1.162 2.70±0.094 2.533±0.153 101.82 0.898 49.000±4.358 
*** Each value is average of twenty independent determinations; **** Each value is average of ten independent determinations, 
*****Each value is average of 216 tablets, ****** Each value is average of six independent determinations. 
 
Statistical and response surface analysis of models 
Statistical analysis 
It was found there was a wide variation in the values of 
disintegration time and friability with change in 
concentration of two factors. Table 6 describes the effect of 
SSG concentrations (2, 4, and 6%) and Ac-Di-Sol 
concentrations (6, 7 and 8%) on the characteristics of IRT. 
Results showed that with increase in concentration of SSG 
and Ac-Di-Sol disintegration time decreased (Patel et al., 
2015)14. The formulation (CT1-CT4) showed unaccepted 
increase in disintegration time (106, 92, 78 and 87 s 
respectively), that exceeded the limits specified for IRTs, 
which is less than 75 s (Dobetti 2012)15 
In case of friability it was found that with increase in 
concentration of SSG and Ac-Di-Sol friability value of IRTs 
also increased. 
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The in vitro drug release data of prepared IRTs is depicted 
graphically in fig.1. According to the dissolution profile it was 
found that the entire batches released drug within 10 min. 
Percentage of drug released from all the formulation varied 
between 95.48-98.86% within 10 min. 
 
 
Figure 1: Percent released of Deflazacort from compressed immediate release tablets. 
Table 6: Effect of superdisintegrant concentration on the characteristics of the prepared immediate release tablet 
formulations of experimental batch 
F. Code 
Sodium starch 
glycolate 
(% w/w) 
Ac-Di-Sol 
(% w/w) 
Hardness(Kg/cm2)**** 
 
Disintegration 
Time (s)****** 
 
Friability***** 
(%) 
 
CT1 2 6 2.8±0.1 106±0.058 0.436 
CT2 4 6 3.01±0.1 92±1.53 0.484 
CT3 6 6 3.1±0.15 78±1.15 0.502 
CT4 2 7 2.67±0.05 87±1 0.492 
CT5 4 7 2.82±0.05 69±1.15 0.574 
CT6 6 7 2.8±0.1 53±0.58 0.592 
CT7 2 8 2.57±0.15 65±1.53 0.586 
CT8 4 8 2.5±0.1 52±1 0.613 
CT9 6 8 2.43±0.05 39±058 0.798 
**** Each value is average of ten independent determinations; *****Each value is average of two hundred sixteen tablets;****** 
Each value is average of six independent determinations 
Optimization 
Optimization was done employing a 32 FFD. The 
dependent and independent variables were related using 
quadratic equations obtained with the Design Expert 
software (Version 7). For each dependent variable, a 
summarizing equation was generated as shown in Table 7. 
ANOVA was performed to identify insignificant factors. 
Model selection was based on lower p values than assigned 
significance level, high F value i.e. 9.68 and 132.42, absence 
of lack of fit, highest level of adjusted R2 and predicted 
R2, low standard deviation and lower PRESS value. All values 
are represented in Table 8. F-value of 9.68 in case of friability 
and 132.42 in case of disintegration time, implies the model 
is significant. High values of R2 for all dependent variables 
were obtained, which indicate a good fit. Adj-R2 and Pred-R2 
values for all responses were in reasonable agreement, 
signifying good model fit. Further, the adequate precision 
value greater than four indicated adequate model 
discrimination. Values of p less than 0.05 indicated that 
model terms are significant. 
 
Table7: The quadratic equations relating friability and disintegration time with independent variables in IRTs tablets. 
Response 
Experimental Parameters 
β0 β1 β2 β3 β4 β5 
Friability 0.55 0.063 0.096 0.037 0.011 0.07 
Disintegration Time 69.44 -14.67 -20.00 0.50 0.33 2.33 
 
Table 8: ANOVA results of full and reduced model for core tablets 
Measured Response SS DF MS F-Value Prob > F SD R2 
Friability 0.085 5 0.017013 9.68 0.0454 0.042 0.9416 
Disintegration time 3702.78 5 740.56 132.42 0.0010 2.36 0.9955 
DF-Degree of freedom; MS-Mean of squares; SS-Sum of squares 
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Response surface analysis 
Response surface plots were generated for each response to 
study the behavior of the system. Response surface plot for 
friability in Fig. 2 shows that with the increase in 
the concentration of SSG and Ac-Di-Sol the friability value of 
the tablet also increases in a linear manner. In case 
of disintegration time Response surface plot (Fig. 3) 
shows that with the increase in the concentration of SSG and 
Ac-Di-Sol the disintegration time decreased in a linear 
manner. 
 
Figure 2: Response surface graph showing the influence 
of X1 and X2 on the friability of immediate release tablets 
of deflazacort 
 
Figure 3: Response surface graph showing the influence 
of X1 and   X2 on the disintegration time of immediate 
release tablet of deflazacort 
Stability studies 
Accelerated stability studies on the optimized promising 
formulation were carried out by storing the tablet at 40 ± 2 
°C and 75 ± 5% RH for 3 months. At regular intervals, the 
formulation was characterized for weight, hardness, 
disintegration time, friability and drug content. It is found 
that there was no change in physical appearance, and other 
tablet characteristics during the study period and at the end 
of the 3 months. Also, no significant change was shown in the 
percent drug release. From the statistical analysis, it was 
found that there was no significant difference between 
before and after storage (P < 0.05). The similarity factor f2 
was calculated to compare the dissolution profiles of 
optimized formulation before and after storage and it was 
found to be 84 which is more than 50 indicating similarity 
between the dissolution profile before and after storage. 
Thus, results imply good stability of the formulation on 3-
month storage. 
CONCLUSION 
It can be concluded from the present study that using 
appropriate concentration of superdisintegrant SSG and Ac-
Di-Sol IRT can be formulated with acceptable values of 
disintegration time and friability. Addition of 
superdisintegrating agent resulted in development of a 
formulation with lesser disintegration time. It was also found 
that above 90% of drug was released within 5 min. due to 
quick disintegration of the tablet. Thus the present 
investigation concluded that it is possible to formulate IRT 
with acceptable physical characteristics having less 
disintegration time and could be used to provide immediate 
relief from the  pain and stiffness that occurs in RA. 
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